Disruptive Pharma is a pharmaceutical development company dedicated to transforming drugs with poor solubility and bioavailability into effective, patient-friendly oral dosage forms. Their proprietary Formulite™ technology, based on mesoporous magnesium carbonate (MMC), enables amorphous formulations that significantly improve solubility, absorption, and oral bioavailability across several drug classes. Their vision is to partner with biotech and pharma companies to turn APIs into commercially attractive products, offering clear advantages in drug delivery.

‍

Since its founding, Disruptive Pharma has built strong partnerships with pharma and biotech companies to turn promising substances into successful medicines. In parallel, the company is developing its own treatments, primarily in cancer where the need for better therapies is especially urgent. With an efficient development process and a clear mission, Disruptive Pharma aims to improve patient outcomes and create new opportunities for the healthcare sector.

‍